Samit Hirawat
Overview
Explore the profile of Samit Hirawat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
3841
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
OBrien N, McDermott M, Conklin D, Luo T, Ayala R, Salgar S, et al.
Breast Cancer Res
. 2020 Aug;
22(1):89.
PMID: 32795346
Background: Combined targeting of CDK4/6 and ER is now the standard of care for patients with advanced ER+/HER2- breast cancer. However, acquired resistance to these therapies frequently leads to disease...
2.
Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo H, et al.
N Engl J Med
. 2019 May;
380(20):1929-1940.
PMID: 31091374
Background: mutations occur in approximately 40% of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. The PI3Kα-specific inhibitor alpelisib has shown antitumor activity in...
3.
Tripathy D, Im S, Colleoni M, Franke F, Bardia A, Harbeck N, et al.
Lancet Oncol
. 2018 May;
19(7):904-915.
PMID: 29804902
Background: In MONALEESA-2, ribociclib plus letrozole showed improved progression-free survival compared with letrozole alone as first-line treatment for postmenopausal patients with hormone receptor (HR)-positive, HER2-negative, advanced breast cancer. MONALEESA-7 aimed...
4.
Soulieres D, Faivre S, Mesia R, Remenar E, Li S, Karpenko A, et al.
Lancet Oncol
. 2017 Jan;
18(3):323-335.
PMID: 28131786
Background: Phosphatidylinositol 3-kinase (PI3K) pathway activation in squamous cell carcinoma of the head and neck contributes to treatment resistance and disease progression. Buparlisib, a pan-PI3K inhibitor, has shown preclinical antitumour...
5.
Hortobagyi G, Stemmer S, Burris H, Yap Y, Sonke G, Paluch-Shimon S, et al.
N Engl J Med
. 2016 Oct;
375(18):1738-1748.
PMID: 27717303
Background: The inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) could potentially overcome or delay resistance to endocrine therapy in advanced breast cancer that is positive for hormone receptor (HR)...
6.
Weetall M, Davis T, Elfring G, Northcutt V, Cao L, Moon Y, et al.
Clin Pharmacol Drug Dev
. 2016 Jun;
5(4):296-305.
PMID: 27310330
PTC299 is a novel small molecule that specifically blocks the production of protein from selected mRNAs that under certain conditions use noncanonical ribosomal translational pathways. Hypoxia, oncogenic transformation, and viral...
7.
Massacesi C, Tomaso E, Urban P, Germa C, Quadt C, Trandafir L, et al.
Onco Targets Ther
. 2016 Jan;
9:203-10.
PMID: 26793003
The PI3K-AKT-mTOR pathway is frequently activated in cancer. PI3K inhibitors, including the pan-PI3K inhibitor buparlisib (BKM120) and the PI3Kα-selective inhibitor alpelisib (BYL719), currently in clinical development by Novartis Oncology, may...
8.
OBrien N, McDonald K, Tong L, Von Euw E, Kalous O, Conklin D, et al.
Clin Cancer Res
. 2014 Jun;
20(13):3507-20.
PMID: 24879796
Purpose: Altered PI3K/mTOR signaling is implicated in the pathogenesis of a number of breast cancers, including those resistant to hormonal and HER2-targeted therapies. Experimental Design: The activity of four classes...
9.
Goteti S, Hirawat S, Massacesi C, Fretault N, Bretz F, Dharan B
J Clin Oncol
. 2014 Feb;
32(8):854-5.
PMID: 24493715
No abstract available.
10.
Saura C, Bendell J, Jerusalem G, Su S, Ru Q, De Buck S, et al.
Clin Cancer Res
. 2014 Jan;
20(7):1935-45.
PMID: 24470511
Purpose: Phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway activation in patients with HER2-positive (HER2(+)) breast cancer has been implicated in de novo and acquired trastuzumab resistance. The purpose of this study was to...